Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2011

View Archived Issues

Takeda presents clinical and preclinical data on TAK-875 in diabetes

Second pivotal phase III Quad study meets primary endpoint

FDA grants priority review to BTG's BLA for experimental methotrexate toxicity treatment

First patient dosed in phase I trial of Marshall Edwards' lead anticancer drug

GWAS identifies new loci linked to susceptibility to Alzheimer's disease

New osteoporosis therapy prevents bone loss by directing mesenchymal stem cells to bone

Orchid Chemicals & Pharmaceuticals discloses new antibacterial oxazolidinone

New broad-spectrum antibacterial compound presented

New brain-penetrant MAPK 10 inhibitor presented as therapeutic candidate for Huntington's disease

Topline phase III data on budesonide MMX to be used to support NDA submission

Novartis launches Onbrez inhalation capsules in Japan

First part of phase I SPI-1620 trial provides encouraging data

SanBio opens phase I/IIa study of neural regenerating cells

FerroKin chelator enters phase II trial in transfusion-dependent pediatric patients with anemia

Novel Mnk inhibitors synthesized at Boehringer Ingelheim Pharma

Novo Nordisk claims new melanocortin receptor modulators

Japan Tobacco presents novel HIV integrase inhibitors

Jazz Pharmaceuticals and Azur Pharma agree to merge

Mitsubishi Tanabe Pharma patents new phosphodiesterase 10A inhibitors

Niiki Pharma reports promising interim phase I data on NKP-1339

Progen to close phase Ia study of PG-545

Bionomics provides update on BNC-105 study in metastatic renal cell carcinoma

PX-102 enters clinical development

European approval of Removab broadened

Sanofi Pasteur and UC San Diego to collaborate on immunological approach to acne

Japanese company discloses novel fatty-acid amide hydrolase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...